What is the recommended dosing for Strattera (atomoxetine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Strattera (Atomoxetine) Dosing

Start atomoxetine at 40 mg once daily in adults and patients over 70 kg, or 0.5 mg/kg/day in children and adolescents up to 70 kg, then increase after a minimum of 3 days to a target dose of 80 mg daily (or 1.2 mg/kg/day), with a maximum of 100 mg daily. 1

Initial Dosing

Children and Adolescents ≤70 kg

  • Starting dose: 0.5 mg/kg/day 1
  • Target dose: 1.2 mg/kg/day after minimum 3 days 1
  • Maximum dose: 1.4 mg/kg/day or 100 mg daily, whichever is less 1
  • Can be given as single morning dose or divided into morning and late afternoon/evening doses 1

Children and Adolescents >70 kg and Adults

  • Starting dose: 40 mg once daily 1
  • Target dose: 80 mg daily after minimum 3 days 1
  • Maximum dose: 100 mg daily after 2-4 additional weeks if optimal response not achieved 1
  • No data support increased effectiveness at doses higher than the target 1

Titration Guidelines

Increase doses slowly at 1-2 week intervals using the smallest available increments to minimize behavioral activation and optimize tolerability. 2

  • Maintain initial dose for at least 1-2 weeks before increasing 2
  • Increase by small increments (typically 10-25 mg) no more frequently than every 1-2 weeks 2
  • Rapid dose escalation can cause behavioral activation, agitation, motor restlessness, insomnia, impulsiveness, and aggression, particularly in younger patients 2
  • If side effects occur, return to the previous well-tolerated dose 2

Special Populations

Hepatic Impairment

  • Moderate hepatic insufficiency (Child-Pugh Class B): Reduce initial and target doses to 50% of normal 1
  • Severe hepatic insufficiency (Child-Pugh Class C): Reduce initial and target doses to 25% of normal 1

CYP2D6 Poor Metabolizers or Concurrent Strong CYP2D6 Inhibitors

When using strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) or in known CYP2D6 poor metabolizers:

  • Children/adolescents ≤70 kg: Start at 0.5 mg/kg/day, increase to 1.2 mg/kg/day only if symptoms fail to improve after 4 weeks and initial dose is well tolerated 1
  • Children/adolescents >70 kg and adults: Start at 40 mg/day, increase to 80 mg/day only if symptoms fail to improve after 4 weeks and initial dose is well tolerated 1

Administration Details

  • Can be taken with or without food 1
  • Capsules must be swallowed whole, not opened 1
  • Can be discontinued without tapering 1
  • Single doses over 120 mg and total daily doses above 150 mg have not been systematically evaluated 1

Timeline for Response

Set appropriate expectations: atomoxetine requires 6-12 weeks to achieve full therapeutic effect, unlike stimulants which work within hours. 2

  • This delayed response timeline is critical for patient adherence 2
  • Symptoms typically return upon discontinuation 2

Safety Monitoring

  • Screen for personal or family history of bipolar disorder, mania, or hypomania before initiating 1
  • Monitor closely for suicidality, clinical worsening, and unusual behavioral changes, especially during the first few months or with dose changes 2
  • Monitor blood pressure and heart rate at baseline, 1 week, and with each dose adjustment 3
  • Common adverse effects include nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence 2

References

Guideline

Risks of Increasing Strattera Dosage

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Risk Assessment for Adding Strattera to Wellbutrin and Effexor

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.